ABSTRACT
BackgroundVirtual presentations have become increasingly common due to the COVID-19 pandemic and advancements in technology. However, it is not yet clear how to effectively use artificial intelligence (AI) in virtual presentations to enhance their effectiveness.ObjectivesThe aim of this study is to investigate the current state of AI in virtual presentations and to develop practical guidelines for using AI to enhance the effectiveness of virtual presentations.MethodsChatGPT is an artificial intelligence chatbot [1]. The final version contains information up to years of 2021. We wrote to ChatGPT: "I want to submit a study for the European League Against Rheumatism (EULAR) 2023. Title: "How to make a virtual presentation using artificial intelligence?”. Prepare a summary consisting of background and objectives sections for me.”. The texts generated by ChatGPT were transferred to another virtual platform to be converted to audio and video. The text in the background and objectives sections in this was voiced by the speaking avatar [2].ResultsChatGPT wrote the background and objectives part of this . As the authors, we have not made any changes in order to be objective. Thanks to another artificial intelligence, the content in this text was voiced by an avatar and turned into a video (Figure 1).ConclusionIn the near future, artificial intelligence will be used more effectively in the preparation and presentation of scientific articles. In this way, artificial intelligence will help scientists to use their time more efficiently. Developing technology also offers equal opportunities for scientists with social phobia and visual or speech disabilities.References[1]GPT-3 [Software]. Retrieved from https://openai.com/[2]synthesia. Retrieved from https://synthesia.ai/Figure 1.Acknowledgements:NIL.Disclosure of InterestsNone Declared.
ABSTRACT
Pediatric multisystem inflammatory syndrome (MIS-C) is a rare disease. It is unknown whether children who have recovered from MIS-C are at risk of MIS-C recurrence when reinfected with SARS-CoV-2. The objective of this study is to describe the cases of two girls who recovered from MIS-C and presented reinfection with SARS-CoV-2 without recurrence of MIS-C.
ABSTRACT
Purpose: The objective of this study was to determine the depression, anxiety, and stress levels of operating room workers during the COVID-19 pandemic.Materials and Methods: The data were collected using the "Personal Information Form" and "Depression Anxiety Stress-21 (DASS-21)" scale. The personal information form consisted of eight questions including age, gender, profession, professional seniority, status of being diagnosed with COVID-19, being afraid of developing COVID-19, presence of chronic diseases and change in weight during the pandemic period. DASS-21 scale is a 4-point Likert type (never=0;always=3) scale and consists of seven questions with each predicting "depression, stress and anxiety dimensions".Results: A total of 253 volunteers with 161 (63.6%) being female and 92 (36.4%) male were included in this observational screening study. Anxiety score of female participants (5.65 +/- 4.44) was found to be statistically significantly higher compared to the male participants (3.94 +/- 4.68). Depression (5.97 +/- 4.41), anxiety (5.48 +/- 4.53) and stress (6.94 +/- 4.59) scores were significantly higher in the participants who were afraid of developing COVID-19. Depression, anxiety and stress scores were significantly higher in the participants with chronic diseases than in those without chronic diseases.Conclusion: The findings of our study indicate that the mean depression, anxiety and stress scores of the operating room personnel were mild.
ABSTRACT
Reactive arthritis is an acute, sterile, non-suppurative and inflammatory arthropathy that usually follows infection process. Gastrointestinal, genitourinary and respiratory tract infections generally provoke reactive arthritis. Also, reactive arthritis can be seen after vaccination. Reactive arthritis cases have been reported after tetanus, combined diphteria-poliomyelitis-tetanus toxoid, hepatitis B or influenza vaccination. Although reactive arthritis is more common in youngs, healthcare workers should be aware of the development of post inactivated COVID-19 vaccine reactive arthritis in older patients. We present two cases with ReA induced by inactivated coronavirus 2019 (COVID-19) vaccination (CoronaVac, Sinovac). Both patients in our study were over 70 years old and presented with polyarthritis that developed after vaccination. Rheumatoid factor and anti-nucleer antibody were negative and patients responded well to short-term steroid therapy, arthritis were not resistant.
ABSTRACT
n/a.
ABSTRACT
Background: TCZ is a monoclonal antibody against Interleukin-6 receptor (IL-6R) which is used for relieving inflammation and reducing mortality in COVID-19 patients. Safety and efficacy of Tocilizumab (TCZ) in Covid-19 pneumonia is uncertain yet. In this study, we aimed to determine clinical outcomes in patients treated with TCZ. Objectives: In this study we aimed to share our retrospective results which we had obtained from patients with COVID-19 diagnosis received TCZ. Methods: We performed a retrospective case control study between May and August 2020 in Turkey. We compared outcomes in patients who received TCZ with those who did not. Death in hospital and intensive care unit (ICU) requirements were evaluated as endpoints. Demographic data, comorbidities, additional treatment, treatment side effects, laboratory and clinical results were retrospectively assessed. There are no significant differences between groups according to age, gender and Charlson Comorbidity Index (CCI). Results: 12 (27.3%) patients died in standard group and eight (18.6%) patients died in TCZ group (p=0.150).Days of staying in the hospital were eight days in standard treatment group and 12 days in TCZ group (p=0.03). 10 of 43 patients in TCZ group were admitted to ICU. MV support was needed in 8 of these patients. 18 of 44 patients (40.9%) within the standard group were admitted to ICU and 12 patients (27.3%) were intubated (p=0.125,p=0.480). Significant IL-6 decrease was not observed post treatment in TCZ group according to pretreatment period (p=0.60). Significant decreases were examined in CRP and ferritin values through TCZ treatment. However, D-dimer and thrombocyte values increased. Conclusion: TCZ may not be an effective treatment for reducing ICU requirement, to prevent intubation or death, for shortening period for staying in hospital. The patients should be followed up closely for possible thrombosis because of increased D-dimer and thrombocytes with TCZ treatment.